Know Cancer

or
forgot password

An Open-label Extension Study to Assess the Safety and Efficacy of Pazopanib in Subjects With Renal Cell Carcinoma Previously Enrolled on Protocol VEG105192


Phase 3
18 Years
N/A
Not Enrolling
Both
Carcinoma, Renal Cell

Thank you

Trial Information

An Open-label Extension Study to Assess the Safety and Efficacy of Pazopanib in Subjects With Renal Cell Carcinoma Previously Enrolled on Protocol VEG105192

Inclusion Criteria


Inclusion criteria:

- Progressed from VEG105192 study treatment

- Patient's VEG105192 was placebo

- Baseline has good organ function

Exclusion criteria:

- No brain metastasis

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Incidence, severity and causality of all adverse events (AE), serious adverse events (SAEs) and other safety parameters Subjects will have a CT/MRI scan every 6 weeks until week 24 and every 12 weeks thereafter

Outcome Time Frame:

approximately 3 years

Safety Issue:

No

Principal Investigator

GSK Clinical Trials

Investigator Role:

Study Director

Investigator Affiliation:

GlaxoSmithKline

Authority:

Austria: Ethikkommission

Study ID:

VEG107769

NCT ID:

NCT00387764

Start Date:

September 2006

Completion Date:

December 2012

Related Keywords:

  • Carcinoma, Renal Cell
  • renal cell carcinoma
  • pazopanib
  • anti-angiogenic therapy
  • open label
  • Carcinoma
  • Carcinoma, Renal Cell

Name

Location